|
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Number of employees : 79 000 people.
|
|
| 2020 | 2021 | Delta | Research & Development Solutions | 5 760.00 | 50.7% | 7 556.00 | 54.5% | +31.18% |
Technology & Analytics Solutions | 4 858.00 | 42.8% | 5 534.00 | 39.9% | +13.92% |
Contract Sales & Medical Solutions | 741.00 | 6.5% | 784.00 | 5.7% | +5.8% |
USD in Million |
|
|
| 2020 | 2021 | Delta | United States | 3 975.65 | 35% | 4 717.16 | 34% | +18.65% |
Europe and Africa | 2 559.10 | 22.5% | 4 357.00 | 31.4% | +70.26% |
Asia-Pacific | 2 245.00 | 19.8% | 2 669.00 | 19.2% | +18.89% |
Americas | 1 443.35 | 12.7% | 2 130.84 | 15.4% | +47.63% |
USD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
256,179,035 |
187,787,305 |
73.3% |
66,900,000 |
26.1% |
73.3% |
|
|
Name | Equities | % | The Vanguard Group, Inc. | 20,464,184 |
10.8% | SSgA Funds Management, Inc. | 8,306,345 |
4.39% | AllianceBernstein LP | 4,219,080 |
2.23% | BlackRock Fund Advisors | 4,000,845 |
2.11% | 3i Investments Plc | 3,958,501 |
2.09% | Geode Capital Management LLC | 3,604,991 |
1.90% | Fidelity Management & Research Co. LLC | 3,578,421 |
1.89% | Leonard Green & Partners LP | 3,376,167 |
1.78% | Longview Partners LLP | 3,140,613 |
1.66% | Farallon Capital Management LLC | 3,117,582 |
1.65% |
|
|
|
- Bloomberg Code : |
|
- Reuters Code : |
IQV.N |
- Datastream Code : |
|
|
Company contact information |
|
Iqvia Holdings Inc. 83 Road Wooster Heights CT 06810 Danbury, Connecticut Phone : +1 203 448 4600 Fax : web site : https://www.iqvia.com
|
|
|
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | IQVIA HOLDINGS INC. | -23.78% | 40 704 |
| | | |
 | MODERNA, INC. | -40.96% | 56 820 |
 | LONZA GROUP AG | -33.17% | 39 547 |
 | SEAGEN INC. | 16.50% | 32 570 |
 | CELLTRION, INC. | -9.60% | 19 048 |
 | ALNYLAM PHARMACEUTICALS, INC. | -13.99% | 17 621 |
 | ICON PUBLIC LIMITED COMPANY | -31.32% | 17 616 |
 | PHARMARON BEIJING CO., LTD. | 1.66% | 16 084 |
 | HANGZHOU TIGERMED CONSULTING CO., LTD | -9.78% | 14 097 |
 | BIO-TECHNE CORPORATION | -31.73% | 13 600 |
 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | -41.92% | 10 871 |
 | QIAGEN N.V. | -13.91% | 10 736 |
 | UNITED THERAPEUTICS CORPORATION | 10.14% | 10 674 |
 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 5.44% | 10 352 |
 | GENSCRIPT BIOTECH CORPORATION | -17.54% | 7 656 |
 | SYNEOS HEALTH, INC. | -30.30% | 7 353 |
 | JOINN LABORATORIES(CHINA)CO.,LTD. | -0.29% | 5 963 |
 | AZENTA, INC. | -31.27% | 5 367 |
 | IONIS PHARMACEUTICALS, INC. | 25.07% | 5 249 |
 | BACHEM HOLDING AG | -49.58% | 5 125 |
 | ALKERMES PLC | 31.26% | 4 890 |
Connections : Iqvia Holdings Inc.
|